PDCD1 and neoplasm: The mutation burden and abundant tumor-associated antigen was of great significance in predicting tumor immunotherapy.[10,11] Unluckily, there was a relatively less frequency of genetic mutations in pituitary adenomas, which was not predictive for cancer immunotherapy.[20] However, recent studies suggested radiotherapy and chemotherapy could enhance PD-1 inhibitors’ efficacy in treating tumor.[21,22] Consequently, it might be reasonable to consider that PD-1 inhibitors could be combined with radiotherapy or temozolomide in treating aggressive pituitary adenomas.